NEW YORK, August 27, 2026, 11:57 (ET) — Propanc stock (PPCB) surged 151% after new PRP data in pancreatic cancer, with trading volume reaching 79 million shares.
- Propanc stock jumped 151.4% to $2.69 as of 11:41 ET.
- About 78.8 million shares changed hands, nearly 20 times the stock’s typical daily volume.
- PRP is still in the preclinical phase; effectiveness has only been observed in animal studies, not in human subjects.
Shares of Propanc Biopharma surged over 100% on Thursday following new data for its PRP therapy in pancreatic cancer. The company said the treatment reduced tumor growth by over 90% in advanced disease models.
The shift in Propanc Biopharma (NASDAQ:PPCB) follows the magnitude of the preclinical data. This does not yet confirm effectiveness in humans.
The stock last changed hands at $2.69 as of 11:41 ET, marking a 151.4% jump from the previous close of $1.07 on Wednesday. The shares opened at $3.51 and rose as high as $4.32. Trading volume totaled 78.8 million shares market data.
Propanc reported that administering PRP intravenously three times per week resulted in over 90% average tumor-growth inhibition. The outcome applied to both orthotopic models and patient-derived xenografts of pancreatic ductal adenocarcinoma.
Median survival was over 2.5 times higher compared to the control group. The company noted a reduction in liver and peritoneal metastases as well. According to its statement, the variation in tumor growth reached statistical significance at p<0.001 Propanc release.
| Investor measure | Latest reading | What it measures |
|---|---|---|
| PPCB share move | +151.4% to $2.69 | Market responds at 11:41 ET |
| Trading volume | 78.8 million | Roughly 20× compared to recent daily norm |
| PRP tumor inhibition | >90% mean | Results in animal testing against vehicle control |
| PRP survival benefit | >2.5× median | Median survival for treated animals vs controls |
| Clinical status | Preclinical | Efficacy in humans unproven |
The key issue for commercial progress is if the signal holds up in human trials. Propanc is preparing a Phase 1b study protocol for as many as 40 patients with advanced solid tumors. The company aims to submit an Australian clinical trial application in the fourth quarter trial plan.
The planned study will initially evaluate safety, tolerability, and dosage. Early indications of activity are a secondary goal. As a result, the next point for valuation is tied to regulatory and operational progress, rather than revenues.
PRP consists of a combination of two pancreatic proenzymes. According to Propanc, the formulation aims to limit recurrence and metastatic progression. The company continues to list the program as preclinical in its pipeline PRP pipeline.
The balance sheet heightens the pressure. As of March 31, Propanc held $443,702 in cash. Over the previous nine months, it consumed $4.08 million in operating cash and did not report any revenue.
The most recent quarterly report showed a nine-month net loss of $14.29 million. Executives warned there is still significant uncertainty over the firm’s ability to stay in business March 2026 Form 10-Q.
No widely circulated Wall Street recommendation consensus was seen on Thursday. As a result, trial funding and dilution remain important considerations for investors, in addition to scientific advancements.
Risks: Outcomes seen in animal studies frequently do not translate to humans. PRP requires regulatory approval, production processes, and safety validation. Propanc faces limited liquidity and ongoing funding requirements, which can increase volatility in returns.
Related articles: Biotechnology
![Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-0051-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]")
